Compare Flagstar Bank NA (FLG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Sanofi SA — how do they compare? Flagstar Bank NA trades at $11.32 (market cap $4.71B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 20.2× Flagstar Bank NA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Flagstar Bank NA for 22 Days and Sanofi SA for 94 Days on average.
| FLG | SNY | |
|---|---|---|
Market Cap | $4.71B | $95.18B |
Volume | 7,410,589 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $15.36 | $52.34 |
52-Week Low | $10.72 | $39.51 |
Typical Hold Time | 22 Days | 94 Days |
Enterprise Value | $15.25B | $114.48B |
Dividend Yield | 0.35% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $11.35, up 0.44% with a bearish technical signal despite recent earnings beats. The stock shows mixed fundamentals with a high P/E of 378.33 but trades below book value at P/B of 0.62. Recent Q2 2026 earnings missed expectations, though the company announced a $250 million share repurchase program and maintains a dividend. Analyst consensus remains bullish with a $17.07 price target.
FLG presents a turnaround opportunity with improving profitability from 2025 losses to 2026 projected net income of $48 million. Key risks include volatile cash flows and competitive banking pressures. The stock's discount to book value and strong analyst support suggest potential upside if execution improves.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
